Is HAEMONETICS CORP (HAE) Halal?

NYSE Healthcare United States $2.5B
✗ NOT HALAL
Confidence: 90/100
HAEMONETICS CORP (HAE) is Not Halal under AAOIFI Standard 21. The company's debt ratio of 40.8% exceeds the 30% threshold, indicating excessive interest-bearing debt relative to market capitalization. HAEMONETICS CORP operates in the Healthcare sector.

Shariah Screening — 5 Standards

Based on financial data from March 2025

Standard Debt Ratio Cash Ratio Receivables Income Status
AAOIFI 40.8%
/ 30%
10.2%
/ 30%
6.8%
/ 30%
1.52%
/ 5%
✗ NOT HALAL
DJIM 40.8%
/ 33%
10.2%
/ 33%
6.8%
/ 33%
1.52%
/ 5%
✗ NOT HALAL
MSCI 50.0%
/ 33%
12.5%
/ 33%
8.3%
/ 33%
1.52%
/ 5%
✗ NOT HALAL
S&P 40.8%
/ 33%
10.2%
/ 33%
6.8%
/ 33%
1.52%
/ 5%
✗ NOT HALAL
FTSE 50.0%
/ 33%
12.5%
/ 33%
8.3%
/ 50%
1.52%
/ 5%
✗ NOT HALAL

Financial Highlights

P/E Ratio
14.9
Forward: 10.2
EPS
$3.63
P/B Ratio
2.8
EV/EBITDA
9.2
EV: $3.4B
Revenue
$1.4B
Growth: -2.7%
Beta
0.3
Low volatility
Current Ratio
1.7

Profitability

Gross Margin 60.2%
Operating Margin 21.0%
Net Margin 13.3%
Return on Equity (ROE) 19.3%
Return on Assets (ROA) 6.4%

Cash Flow & Balance Sheet

Operating Cash Flow$182M
Free Cash Flow$142M
Total Debt$1.2B
Debt-to-Equity134.4
Current Ratio1.7
Total Assets$2.5B

Price & Trading

Last Close$55.52
50-Day MA$62.60
200-Day MA$65.29
Avg Volume850K
Beta0.3
52-Week Range
$47.32
$87.32

About HAEMONETICS CORP (HAE)

CEO
Mr. Christopher A. Simon
Employees
3,023
Sector
Healthcare
Industry
Medical Devices
Country
United States
Exchange
NYSE
Market Cap
$2.5B
Currency
USD

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. It also provides treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE closure products comprising VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, clinical specialists, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Related Halal Stocks in Healthcare

Frequently Asked Questions

Is HAEMONETICS CORP (HAE) halal to invest in?

Based on our screening using AAOIFI Standard 21 (the strictest methodology), HAEMONETICS CORP is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.

What is HAEMONETICS CORP's debt ratio?

HAEMONETICS CORP's debt ratio is 40.8% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 50.0%.

What are HAEMONETICS CORP's key financial metrics?

HAEMONETICS CORP has a market capitalization of $2.5B, trailing P/E ratio of 14.9, and revenue of $1.4B. The company maintains a gross margin of 60.2% and a net margin of 13.3%. Return on equity stands at 19.3%.

How often is the screening data updated?

Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.